Apellis Pharmaceuticals, Inc. is a forward-looking clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focusing on the development of novel therapeutic compounds targeting the complement system to treat autoimmune and inflammatory diseases. The company's innovative pipeline, underscored by its flagship asset, aims to revolutionize treatment options for patients with complex conditions, highlighting Apellis' commitment to delivering transformative therapies. As a significant player in the biopharmaceutical landscape, Apellis is well-positioned to address unmet medical needs while advancing the science of complement inhibition.